FDA-cleared profile

QOCA image Smart CXR Image Processing System

Quanta Computer Inc. · X-ray/Radiography · FDA-cleared (510(k))

Authorized purpose: QOCA image Smart CXR analyzes adult chest X-ray images and flags cases with suspected pneumothorax to support prioritization for radiologist review.

Clinical role
Passive case-level triage notification within the radiologist worklist; no cases are removed from the standard workflow.
Images and patients
X-ray/Radiography · Chest/Lung
Key limitation
Keep in mind: The output is not a substitute for radiologist diagnosis and is not for standalone clinical decision-making. It is limited to PA or AP erect adult chest radiographs and does not directly indicate image locations or anomalies.

Overview status: Source-reviewed overview

Report a correction
Clinical details Purpose, workflow fit, evidence, and safety record

Workflow navigation pilot

Workflow role has not yet been reviewed for this navigation pilot.

A tag identifies a documented role; it does not establish compatibility or local acceptance. Methods and sources

  • What does this software do?Authorized purpose: QOCA image Smart CXR analyzes adult chest X-ray images and flags cases with suspected pneumothorax to support prioritization for radiologist review.
  • Which images or clinical context are in scope?Modality: X-ray/Radiography Anatomy or clinical context: Chest/Lung Input: Adult chest radiographs in PA or AP erect view, received as DICOM files pushed from PACS.
  • Who uses it?Intended users: Radiologists reviewing adult chest radiographs.
  • What does the software produce?Output: A notation beside cases with suspected pneumothorax for radiologist prioritization; it does not directly mark the image location or anomaly.
  • What is its most important limitation?Key limitation: The output is not a substitute for radiologist diagnosis and is not for standalone clinical decision-making. It is limited to PA or AP erect adult chest radiographs and does not directly indicate image locations or anomalies.

Clinical takeaway. Clinical role: QOCA image Smart CXR analyzes adult chest X-ray images and flags cases with suspected pneumothorax to support prioritization for radiologist review.

Evidence takeaway. Evidence from the reviewed source record: The performance of the subject device, QOCA® image Smart CXR Image Processing System, has been validated in two separate pivotal studies. The performance of the subject device across the performance assessment dataset achieves an area under the curve (AUC) of 97.8% (95% CI: [97.0%, 98.5%]); in addition, the sensitivity and specificity achieves 92.5% (95% CI: [90.5%, 94.2%]), 94.0% (95% CI: [93.9%, 94.6%]) respectively, without subgroup breakdown.

Evidence context

Evidence context not reviewed for this FDA record.

Public-label constraints

Label constraints have not been reviewed for this exact FDA record. Unknown is not all ages or evidence of unsuitability.

Public-label constraints, not patient-level eligibility or a medical recommendation. Training and evaluation populations are separate. Read the original labeling and confirm the exact release and protocol.

Purpose
QOCA image Smart CXR analyzes adult chest X-ray images and flags cases with suspected pneumothorax to support prioritization for radiologist review.
  • Exact FDA submission
  • Checked 2026-09-19

Clinical-use display mirrors the exact FDA-supported purpose reconciled from the decision-summary packet.

Workflow role
Passive case-level triage notification within the radiologist worklist; no cases are removed from the standard workflow.
  • Exact FDA submission
  • Checked 2026-09-14
Required input
Adult chest radiographs in PA or AP erect view, received as DICOM files pushed from PACS.
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Output and clinician action
A notation beside cases with suspected pneumothorax for radiologist prioritization; it does not directly mark the image location or anomaly.
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Care setting
Hospital PACS workflow for adult chest radiographs.
  • Exact FDA submission
  • Checked 2026-09-14
Intended users
Radiologists reviewing adult chest radiographs.
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Limitations
The output is not a substitute for radiologist diagnosis and is not for standalone clinical decision-making. It is limited to PA or AP erect adult chest radiographs and does not directly indicate image locations or anomalies.
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Evidence summary
The performance of the subject device, QOCA® image Smart CXR Image Processing System, has been validated in two separate pivotal studies. The performance of the subject device across the performance assessment dataset achieves an area under the curve (AUC) of 97.8% (95% CI: [97.0%, 98.5%]); in addition, the sensitivity and specificity achieves 92.5% (95% CI: [90.5%, 94.2%]), 94.0% (95% CI: [93.9%, 94.6%]) respectively, without subgroup breakdown.
  • Exact FDA submission
  • Checked 2026-09-19

The replacement uses the packet's pivotal-study and aggregate performance results without adding an independent-outcome characterization.

Evidence

Performance evidence

Metrics are shown only when they are tied to a source, endpoint, population, and tested product version. Candidate literature without exact product and version linkage is not shown as product evidence.

Evidence summary
The performance of the subject device, QOCA® image Smart CXR Image Processing System, has been validated in two separate pivotal studies. The performance of the subject device across the performance assessment dataset achieves an area under the curve (AUC) of 97.8% (95% CI: [97.0%, 98.5%]); in addition, the sensitivity and specificity achieves 92.5% (95% CI: [90.5%, 94.2%]), 94.0% (95% CI: [93.9%, 94.6%]) respectively, without subgroup breakdown.
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

The replacement uses the packet's pivotal-study and aggregate performance results without adding an independent-outcome characterization.

Reported sensitivity
92.5% (95% CI: 90.5%, 94.2%)
  • Public source
  • Exact FDA submission
  • Checked 2026-09-01

Model sensitivity reported by ACR AI Central. Review endpoint, threshold, study population, and tested version before comparison.

Reported specificity
94.0% (95% CI: 93.9%, 94.6%)
  • Public source
  • Exact FDA submission
  • Checked 2026-09-01

Model specificity reported by ACR AI Central. Review endpoint, threshold, study population, and tested version before comparison.

No contextualized exact-version metric has completed evidence review. Regulatory-document values, when available, are shown above with their limitations.

QOCA image Smart CXR Image Processing System regulatory performance study summary

  • DesignStand-Alone Performance
  • PopulationAdult
  • Scopeexact submission
  • Tested versionExact product version not reported; regulatory study summarized for FDA submission K221868
  • Samplen=6052
  • IndependenceIndependence not established

K221868

ACR AI Central summarizes the regulatory study; consult the exact FDA materials before comparative use.

Safety and lifecycle

Postmarket record

Recall and adverse-event records are shown only after product matching. Adverse-event reports do not establish incidence or causality.

Postmarket safety review
Candidate records await review
  • Human review pending
  • Exact FDA submission
  • Checked 2026-09-14

Exact-submission postmarket candidates remain quarantined pending a separate source review.

Pricing & contracts Public price, contract terms, and reimbursement

Price not public here; enter your quote

Not verified: Pricing information is recorded but not verified against a resolving source.

Reimbursement

IT implementation Deployment, interfaces, data handling, and support

System and version relationships

Match the AI release, system build, configuration and region. Source documentation does not establish acceptance of an installed system.

No specific system/version pairing has completed review for this FDA record. A broad DICOM or product-family statement does not establish a named viewer build's support.

Review Merge, Visage, Sectra, AGFA and IntelePACS context

Integration chain: evidence at each hop

Public source context, not tested interoperability. Each hop needs its own release/configuration evidence. Missing or unavailable routes are not documented incompatibility. All local tests are planned, not passed; no installed-system acceptance is recorded.

Acquisition/source → routing → AI processing → returned objects → viewer/worklist/report → support owner

No specific route context has been source-reviewed for this record. Obtain both endpoint builds and documents; this is not a finding of incompatibility.

  1. Acquisition/source

    Source context, not route validation: Adult chest radiographs in PA or AP erect view, received as DICOM files pushed from PACS.

    Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

    Confirm scanner/model, protocol, series completeness and both software builds.

    Field checked 2026-09-19 · K221868 FDA 510(k) decision summary

  2. Routing

    Source context, not route validation: The device connects with hospital PACS, analyzes DICOM files pushed from PACS, and presents case-level notations in its viewer. Exact local interface compatibility requires site validation.

    Scope: Exact FDA submission.

    Name gateways, destinations, transfer rules and failure visibility; a DICOM statement does not prove a route.

    Field checked 2026-09-14 · K221868 FDA 510(k) decision summary

  3. AI processing

    Source context, not route validation: The exact FDA package describes QOCA image Smart CXR as a web-based medical device that provides case sorting and image viewing and supports multiple users at a time. Current hosting, data flow, and commercial configuration require vendor confirmation.

    Scope: Exact FDA submission. Packet wording: "QOCA® image Smart CXR Image Processing System, is a web-based medical device using a locked artificial intelligence algorithm." … "provides features such as cases sorting and image viewing, and supports multiple users at a time.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

    Confirm processing location, queue ownership, exclusions and exact AI build.

    Field checked 2026-11-14 · K221868 FDA 510(k) decision summary

  4. Returned objects

    Source context, not route validation: A notation beside cases with suspected pneumothorax for radiologist prioritization; it does not directly mark the image location or anomaly.

    Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

    Confirm object classes, units, references and whether findings, overlays or measurements reach their intended destination.

    Field checked 2026-09-19 · K221868 FDA 510(k) decision summary

  5. Viewer/worklist/report

    Unresolved route: A notation beside cases with suspected pneumothorax for radiologist prioritization; it does not directly mark the image location or anomaly.

    Scope: Exact FDA submission. Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

    Confirm the named viewer/worklist/report build, display behavior and report transfer. Output support alone does not establish this endpoint. The displayed source describes output, not validated end-to-end delivery.

    Field checked 2026-09-19 · K221868 FDA 510(k) decision summary

  6. Support owner

    Unresolved route: Not established for the exact route.

    Scope: Scope not established.

    Name the local, platform and AI supplier support owners and escalation path.

Planned local route tests

No tests below have been performed or accepted.

  1. Patient/study identity (planned). Use approved non-patient test data to verify identifiers, accession and result-to-study linkage at every hop.
  2. Study completeness (planned). Test missing views/series, partial transfer, late arrivals, priors and unsupported acquisition inputs; confirm explicit refusal or fallback.
  3. Ordering and duplicates (planned). Send out-of-order, repeated and corrected studies; verify worklist order, deduplication and no misleading stale results.
  4. Report transfer (planned). Verify output object types, annotations, units, report content, destination and availability of original images.
  5. Access (planned). Verify authorized roles, audit trail, denied access and support ownership at each destination.
  6. Latency and failures (planned). Agree a workload and turnaround target; test queues, timeouts, missing results and fallback reading.
  7. Updates and rollback (planned). Define version change control, revalidation triggers, stop-use criteria and a tested rollback route.

Local implementation checklist

Agree the evidence and acceptance owner with your team and suppliers. Checkmarks apply to this page only and are not acceptance receipts.

Open the printable evaluation checklist

Deployment
The exact FDA package describes QOCA image Smart CXR as a web-based medical device that provides case sorting and image viewing and supports multiple users at a time. Current hosting, data flow, and commercial configuration require vendor confirmation.
  • Exact FDA submission
  • Checked 2026-11-14

Packet wording: "QOCA® image Smart CXR Image Processing System, is a web-based medical device using a locked artificial intelligence algorithm." … "provides features such as cases sorting and image viewing, and supports multiple users at a time.". Read from the exact FDA decision document on 2026-11-14; this is the release-level description, not current commercial configuration.

Integration
The device connects with hospital PACS, analyzes DICOM files pushed from PACS, and presents case-level notations in its viewer. Exact local interface compatibility requires site validation.
  • Exact FDA submission
  • Checked 2026-09-14

Input and worklist workflow

The FDA packet describes DICOM intake from hospital PACS and passive worklist notation for radiologist review.

exact submission · checked 2026-09-14

Confirm supported PACS versions, routing, and viewer behavior locally.

Sources & review details FDA identity, research record, source ledger, and history

Regulatory identity

FDA record and catalog context

The FDA listing establishes the regulatory identity. It does not by itself establish local workflow fit, pricing, security, or performance in your environment.

FDA submission
K221868
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Modality
X-ray/Radiography
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Anatomy
Chest/Lung
  • FDA source
  • Exact FDA submission
  • Checked 2026-09-19

Exact FDA decision-summary packet reviewed on 2026-09-19; existing wording is supported without expansion.

Clearance type
510(k)
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
Decision date
2023-01-27
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31
FDA status
FDA-cleared
  • FDA source
  • Exact FDA submission
  • Checked 2026-08-31

Research record

What has been checked

This audit distinguishes completed source review from fields that have not yet been researched.

Exact FDA record reviewedStatus
2026-09-20Last searched
28Fields reviewed
9Source classes checked
0Screened PubMed leads
0Screened trial leads
0Unreviewed FDA recall leads

The refreshed discovery snapshot contains no PubMed or ClinicalTrials.gov candidates; no external evidence was promoted. The current discovery snapshot contains 0 PubMed and 0 ClinicalTrials.gov candidate records; its dated, count-matched human screening remains current. Unlinked candidates remain quarantined. Native FDA recall identifiers produced 0 postmarket candidate records; 0 have been reviewed (0 published, 0 rejected) and 0 remain unreviewed.

Candidate leads were screened against the exact product and tested version. Unlinked records remain quarantined.

Source classes: fda ai list, fda decision summary, acr ai central product, fda decision summary packet, literature index, trial registry, pubmed, clinical trials, openfda device recall

Field review details

Recorded state, verification date, notes and sources for fields without a publishable value. Conflicting records stay explicitly unsettled here; no plain settled value is shown for them.

  • Public pricing: Not verified - checked 2026-09-14 - Exact FDA submission

    No current exact-product price, contract term, or implementation fee was established.

  • Pricing model: Not yet reviewed
  • Setup and integration fees: Not yet reviewed
  • Recurring fees: Not yet reviewed
  • Minimum commitment: Not yet reviewed
  • Contract duration: Not yet reviewed
  • Renewal terms: Not yet reviewed
  • Cancellation terms: Not yet reviewed
  • Support and service terms: Not yet reviewed
  • Trial or pilot terms: Not yet reviewed
  • Reimbursement: Not publicly available - checked 2026-09-14 - Exact FDA submission

    No exact-product payer policy, coding instruction, or payment determination was established.

  • Data hosting location: Not yet reviewed
  • Data retention: Not yet reviewed
  • Documented data use: Not yet reviewed
  • Hardware requirements: Not yet reviewed
  • Network requirements: Not yet reviewed
  • Identity and access: Not yet reviewed
  • Security: Not verified - checked 2026-09-14 - Exact FDA submission

    Current security controls, data retention, access model, and assurance documentation require vendor confirmation.

  • Installation timeline: Not yet reviewed
  • Training: Not verified - checked 2026-09-14 - Exact FDA submission

    Current training, competency, and support commitments require vendor confirmation.

  • Monitoring: Not verified - checked 2026-09-14 - Exact FDA submission

    Site-specific quality monitoring, update control, escalation, and incident-response commitments require vendor and local governance evidence.

6 sources - 3 history items

Source ledger

  1. K221868 FDA 510(k) decision summary

    U.S. Food and Drug Administration - Published 2023-01-27 - Accessed 2026-09-19

    Scope: purpose, modality, anatomy, intendedUsers, workflowRole, input, output, careSetting, limitations, evidenceSummary, integration, clinicalUse, deployment

  2. Artificial Intelligence-Enabled Medical Devices

    U.S. Food and Drug Administration - Accessed 2026-08-31

    Scope: regulatoryIdentity, modalityContext

  3. QOCA image Smart CXR Image Processing System model card (K221868)

    American College of Radiology - Published 2026-08-17 - Accessed 2026-09-01

    Scope: intendedUsers, careSetting, output, limitations, reportedSensitivity, reportedSpecificity, evidenceSummary, integration, anatomy, evidenceStudies, implementationCapabilities

  4. PubMed biomedical literature index

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery

  5. ClinicalTrials.gov study registry

    U.S. National Library of Medicine - Accessed 2026-09-01

    Scope: evidenceDiscovery, studyStatus

  6. openFDA Device Recall API

    U.S. Food and Drug Administration - Accessed 2026-09-02

    Scope: recallDiscovery, nativeSubmissionMatching

Research history

  1. K221868 FDA decision

    Regulatory record

    510(k)

  2. Source-review record updated

    Research record

    fda record reviewed

  3. Reader overview source-reviewed

    Editorial review

    Source-reviewed editorial overlay

Alternatives

Related tools to compare

FDA-cleared K243808

Rayvolve PTX-PE

AZmed

Authorized purpose: Passive study-level worklist triage for suspected pneumothorax and/or pleural effusion on adult PA or AP chest X-rays; it is not a proactive specialist alert.

Modality
X-ray/Radiography
Anatomy
Chest/Lung
Decision
2025-03-21
FDA-cleared K232410

SmartChest

Milvue

Authorized purpose: Passive worklist prioritization for suspected pleural effusion and/or pneumothorax on frontal PA or AP chest radiographs in transitional adolescents aged 18-21 and adults aged 22 years and older; not diagnostic or a rule-out function.

Modality
X-ray/Radiography
Anatomy
Chest/lung
Decision
2024-05-10

Correct this exact record

Copy this public context and add the field, proposed wording and original source before sending. Nothing here is submitted automatically. Form-specific prefill has not been verified.

Open existing correction destination

Permission to display a submission is not evidence verification. A submission enters editorial review; it does not approve a public change. Form availability, data entry, receipt, review and publication are separate steps. Data entry and receipt remain unverified.

Accepted repository change history

No entry has been added to this scoped change history for this record. This is not proof that the record never changed.

Correction policy and limits · Public repository change history